SCHEMBL4846626

SCHEMBL4846626

FC(F)(F)c1ccc(-c2cc(Nc3ccc4c(c3)OCCO4)ccn2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 3/20 0.71
MAPT P10636 2/20 0.47
CLK1 P49759 3/20 0.47
CLK2 P49760 3/20 0.47
DYRK1A Q13627 3/20 0.47
CLK4 Q9HAZ1 3/20 0.47
DYRK1B Q9Y463 3/20 0.47
GSK3B P49841 2/20 0.44
ALOX5 P09917 1/20 0.44
ABL1 P00519 1/20 0.43
BCR P11274 1/20 0.43
CDK2 P24941 1/20 0.43
ADRA2A P08913 1/20 0.43
ADRA2B P18089 1/20 0.43
ADRA2C P18825 1/20 0.43
ADRA1D P25100 1/20 0.43
ADRA1A P35348 1/20 0.43
ADRA1B P35368 1/20 0.43
ULK1 O75385 1/20 0.43
MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1013650 0.83 TRPV1 (1.00) TRPV1MAPTABL1BCR
SCHEMBL13675611 0.82 TRPV1 (0.70) TRPV1MAPTCLK1CLK2DYRK1A
SCHEMBL14082702 0.79 RAB9A (0.58) TRPV1MAPTMEN1NPC1ALDH1A1
SCHEMBL12297542 0.78 ALOX5 (0.73) TRPV1MAPTALOX5MEN1NPC1
SCHEMBL4836061 0.76 TRPV1 (0.87) TRPV1MAPTDYRK1ACLK4ABL1
SCHEMBL7089033 0.76 TRPV1 (0.54) TRPV1MAPTADRA2AADRA2BADRA2C
SCHEMBL3996428 0.75 TRPV1 (0.60) TRPV1MAPTCLK1CLK2DYRK1A
SCHEMBL4000052 0.73 TRPV1 (0.58) TRPV1MAPTCLK1CLK2DYRK1A
SCHEMBL25755088 0.73 KIF11 (0.56) TRPV1GSK3BABL1BCR
SCHEMBL4833186 0.72 TRPV1 (0.80) TRPV1DYRK1ACLK4ABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7390907-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2008-06-24 US claimed
EP-1775295-A1 Vanilloid receptor ligands and their use in treatments Amgen Inc. (US) 2007-04-18 EP claimed
EP-1670794-A2 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS Amgen Inc. (US) 2006-06-21 EP claimed
US-20050153984-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2005-07-14 US claimed
WO-2005033105-A2 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2005-04-14 WO claimed
US-7390907-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2008-06-24 US disclosed
US-7390907-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2008-06-24 US disclosed
US-7390907-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2008-06-24 US disclosed
EP-1780211-A2 Vanilloid receptor ligands and their use in treatments Amgen Inc. (US) 2007-05-02 EP disclosed
EP-1780211-A2 Vanilloid receptor ligands and their use in treatments Amgen Inc. (US) 2007-05-02 EP disclosed
EP-1775295-A1 Vanilloid receptor ligands and their use in treatments Amgen Inc. (US) 2007-04-18 EP disclosed
EP-1775295-A1 Vanilloid receptor ligands and their use in treatments Amgen Inc. (US) 2007-04-18 EP disclosed
US-20050153984-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2005-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050153984-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV2, TRPV3 TRPV1 1/4885MAPT 716/4885CLK1 4790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.